What makes us special?

For over 15 years, Richmond Pharmacology has delivered clinical excellence from design to delivery of early phase clinical trials, going from strength to strength in a fiercely competitive market place. We have experience that is held by our long serving management team and are reputed for our customer focus, flexible approach and strong project management. We have conducted over 300 Early Phase Studies.

We have developed an efficient approach that allows us to combine different designs into one protocol, leading to objectively faster development times from First in Human to Proof of Concept studies. Our integrated platform is designed to streamline every aspect of Early Phase trials with quality, integrity and accuracy.

What makes us special is that we are well established in a competitive market place and are a recognised stakeholder on a national, European and global level, helping drive the clinical research sector forward. We are intellectually engaged, adding value by working with our clients to achieve the best possible outcomes for them. We are small enough to care and to be personable, yet large enough to perform well in the largest of studies.

We are highly specialised in Adaptive Phase I, QT studies, Japanese and Patient studies. Richmond’s volunteer database is the single largest of its type worldwide with over 250,000 registered volunteers actively seeking to take part in a clinical trial. The intelligence we gather enables us to make firm commitments and to adhere to agreed timelines. We are attentive and thorough in our attitude. We deliver a professional and courteous service establishing long-term working relationships with our clients.

More about our Specialist Services

Latest news

DIA, Chicago 2017

23rd Jun 2017

Richmond Pharmacology is a frequent contributor and recognised thought leader for various scientific meetings

Read more ›

Richmond Pharmacology’s New London Bridge unit offers unrivalled access to patient recruitment

28th Apr 2017

Richmond Pharmacology has been settling into life in its New London Bridge Research Unit.

Read more ›

New CRO unit facility welcomes first overnight patients

31st Mar 2017

Richmond Pharmacology has been busy settling in their first patients at the new London Bridge site.

Read more ›

American Society for Clinical Pharmacology and Therapeutics (ASCPT)

Mar 15th 2017 | Washington, D.C

Richmond Pharmacology is attending the American Society for Clinical Pharmacology and Therapeutics (ASCPT) event in Washington DC over the next few days.

View all events ›